Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Lung Cancer
Hepatocellular Cancer
Colorectal Cancer
Pancreatic Cancer
Renal Cancer

Interventions

DRUG: NIS793
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals